OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Disease modification and biomarker development in Parkinson disease
Alberto J. Espay, Lorraine V. Kalia, Ziv Gan‐Or, et al.
Neurology (2020) Vol. 94, Iss. 11, pp. 481-494
Open Access | Times Cited: 115

Showing 1-25 of 115 citing articles:

Progress towards therapies for disease modification in Parkinson's disease
Nirosen Vijiaratnam, Tanya Simuni, Oliver Bandmann, et al.
The Lancet Neurology (2021) Vol. 20, Iss. 7, pp. 559-572
Open Access | Times Cited: 243

The heterogeneity of Parkinson’s disease
Ullrich Wüllner, Per Borghammer, Chi‐un Choe, et al.
Journal of Neural Transmission (2023) Vol. 130, Iss. 6, pp. 827-838
Open Access | Times Cited: 67

Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2020
Kevin McFarthing, Sue Buff, Gary Rafaloff, et al.
Journal of Parkinson s Disease (2020) Vol. 10, Iss. 3, pp. 757-774
Open Access | Times Cited: 120

GBA‐Related Parkinson's Disease: Dissection of Genotype–Phenotype Correlates in a Large Italian Cohort
Simona Petrucci, Monia Ginevrino, Ilaria Trezzi, et al.
Movement Disorders (2020) Vol. 35, Iss. 11, pp. 2106-2111
Open Access | Times Cited: 115

Reappraisal of metabolic dysfunction in neurodegeneration: Focus on mitochondrial function and calcium signaling
Pooja Jadiya, Joanne F. Garbincius, John W. Elrod
Acta Neuropathologica Communications (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 59

Resveratrol and neuroprotection: an insight into prospective therapeutic approaches against Alzheimer’s disease from bench to bedside
Fahadul Islam, Mohamed H. Nafady, Md. Rezaul Islam, et al.
Molecular Neurobiology (2022) Vol. 59, Iss. 7, pp. 4384-4404
Closed Access | Times Cited: 58

Duodenal alpha‐Synuclein Pathology and Enteric Gliosis in Advanced Parkinson's Disease
Aron Emmi, Michele Sandre, Francesco Paolo Russo, et al.
Movement Disorders (2023) Vol. 38, Iss. 5, pp. 885-894
Open Access | Times Cited: 29

Epigenetic modification in Parkinson’s disease
Hao Song, Juanli Chen, Jin Huang, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 23

Transitioning from Subtyping to Precision Medicine in Parkinson's Disease: A Purpose‐Driven Approach
Connie Marras, Seyed‐Mohammad Fereshtehnejad, Daniela Berg, et al.
Movement Disorders (2024) Vol. 39, Iss. 3, pp. 462-471
Open Access | Times Cited: 15

Retinal Thickness Predicts the Risk of Cognitive Decline in Parkinson Disease
Ane Murueta‐Goyena, Rocío Del Pino, Marta Galdós, et al.
Annals of Neurology (2020) Vol. 89, Iss. 1, pp. 165-176
Open Access | Times Cited: 59

New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin
Konstantin Senkevich, Uladzislau Rudakou, Ziv Gan‐Or
Neuropharmacology (2021) Vol. 202, pp. 108822-108822
Closed Access | Times Cited: 53

The Disease Modification Conundrum in Parkinson’s Disease: Failures and Hopes
Zoltán Mari, Tiago Mestre
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 30

Finding the falsification threshold of the toxic proteinopathy hypothesis in neurodegeneration
Alberto J. Espay, Karl Herrup, Timothy Daly
Handbook of clinical neurology (2023), pp. 143-154
Closed Access | Times Cited: 18

Upregulated ECM genes and increased synaptic activity in Parkinson’s human DA neurons with PINK1/ PRKN mutations
Utkarsh Tripathi, Idan Rosh, Ran Ben Ezer, et al.
npj Parkinson s Disease (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 7

Seven Solutions for Neuroprotection in Parkinson's Disease
David Devos, Étienne C. Hirsch, Richard Wyse
Movement Disorders (2020) Vol. 36, Iss. 2, pp. 306-316
Open Access | Times Cited: 42

The Future of GDNF in Parkinson's Disease
Fredric P. Manfredsson, Nicole K. Polinski, Thyagarajan Subramanian, et al.
Frontiers in Aging Neuroscience (2020) Vol. 12
Open Access | Times Cited: 41

Worldwide barriers to genetic testing for movement disorders
Emilia Gatto, Ruth H. Walker, Claudio González, et al.
European Journal of Neurology (2021) Vol. 28, Iss. 6, pp. 1901-1909
Open Access | Times Cited: 37

The Olfactory System as Marker of Neurodegeneration in Aging, Neurological and Neuropsychiatric Disorders
Naina Bhatia‐Dey, Thomas Heinbockel
International Journal of Environmental Research and Public Health (2021) Vol. 18, Iss. 13, pp. 6976-6976
Open Access | Times Cited: 36

Alpha-synuclein oligomers and small nerve fiber pathology in skin are potential biomarkers of Parkinson’s disease
Elena Vacchi, Camilla Senese, Giacomo Chiaro, et al.
npj Parkinson s Disease (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 36

Identification of Parkinson's Disease Subtypes from Resting‐State Electroencephalography
Sahar Yassine, Ute Gschwandtner, Manon Auffret, et al.
Movement Disorders (2023) Vol. 38, Iss. 8, pp. 1451-1460
Open Access | Times Cited: 16

Searching for Biomarkers in the Blood of Patients at Risk of Developing Parkinson’s Disease at the Prodromal Stage
Е А Катунина, V. E. Blokhin, M. R. Nodel, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 1842-1842
Open Access | Times Cited: 15

In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease
D. L. Price, Asma Khan, Rachel Angers, et al.
npj Parkinson s Disease (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 15

Recalibrating the Why and Whom of Animal Models in Parkinson Disease: A Clinician’s Perspective
Andrea Sturchio, Emily M. Rocha, Marcelo Kauffman, et al.
Brain Sciences (2024) Vol. 14, Iss. 2, pp. 151-151
Open Access | Times Cited: 5

Additive neurorestorative effects of exercise and docosahexaenoic acid intake in a mouse model of Parkinson’s disease
Olivier Kerdiles, Méryl-Farelle Oye Mintsa Mi-mba, Katherine Coulombe, et al.
Neural Regeneration Research (2024) Vol. 20, Iss. 2, pp. 574-586
Open Access | Times Cited: 5

A Study on Voice Measures in Patients with Parkinson’s Disease
Noé Xiu, Wenmei Li, Lu Liu, et al.
Journal of Voice (2024)
Closed Access | Times Cited: 5

Page 1 - Next Page

Scroll to top